By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Kyowa Hakko Kirin 

Ohtemachi Building 5F
1-6-1 Ohtemachi, Chiyoda-ku
Tokyo    100-8185  Japan
Phone: 81-3-3282-0007 Fax: 81-3-3284-1968



Company News
Kyowa Hakko Kirin Joins Certara Corporation’s Simcyp Consortium 9/13/2017 7:42:32 AM
Ultragenyx (RARE) And Kyowa Hakko Kirin Announce Submission Of Burosumab’s Biologics License Application In The U.S. 8/24/2017 8:08:52 AM
Ultragenyx (RARE), Kyowa Hakko Kirin And Kyowa Kirin International Announce Positive 24-Week Data From Adult Phase II Study Of Burosumab (KRN23) In X-Linked Hypophosphatemia 4/19/2017 10:39:10 AM
GHIT Fund Welcomes Ten New Partnerships With FUJIFILM, Otsuka, GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Kyowa Hakko Kirin, Merck & Co. (MRK), Mitsubishi Tanabe, Nipro Corporation, Sumitomo Dainippon Pharma Co., Ltd. And Salesforce.Com 6/6/2016 12:09:47 PM
Kyowa Hakko Kirin And Bristol-Myers Squibb (BMY) Announce Immuno-Oncology Clinical Collaboration Studying Mogamulizumab And Opdivo (Nivolumab) In Advanced Solid Tumors In The U.S. 7/30/2015 12:48:04 PM
Syndax Pharmaceuticals Inc. Snags $125 Million Deal With Kyowa Hakko Kirin 1/8/2015 7:34:35 AM
Ono Pharmaceutical Company, Ltd., Bristol-Myers Squibb Company (BMY), And Kyowa Hakko Kirin Announce Immuno-Oncology Clinical Collaboration Studying Opdivo (Nivolumab) And Mogamulizumab In Advanced Solid Tumors 12/10/2014 9:19:38 AM
Pfizer (PFE) And Kyowa Hakko Kirin To Collaborate On Immuno-Oncology Combination Study 9/30/2014 10:19:02 AM
Pfizer (PFE), Kyowa Hakko Kirin Team Up On Immuno-Oncology Combination Study 9/30/2014 6:05:52 AM
ArQule, Inc. (ARQL) Announces Commencement Of Phase 3 Clinical Trial With Tivantinib In Hepatocellular Carcinoma By Partner Kyowa Hakko Kirin In Japan 2/4/2014 9:46:24 AM